查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1937784

全球肌萎缩侧索硬化症治疗市场规模、份额、趋势和成长分析报告（2026-2034年）

Global Amyotrophic Lateral Sclerosis Treatment Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 136 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

肌萎缩侧索硬化症 (ALS) 治疗市场规模预计将从 2025 年的 8.0136 亿美元增长到 2034 年的 12.6033 亿美元，2026 年至 2034 年的复合年增长率为 5.16%。

肌萎缩侧索硬化症 (ALS) 治疗市场正经历显着成长，这主要得益于这种神经退化性疾病盛行率的不断上升以及治疗方案的不断进步。 ALS 的特征是运动神经元进行性退化，其复杂的病理学为治疗带来了独特的挑战。然而，近年来，疾病修正治疗（例如Riluzole和Edaravone）的进展已显示出在延缓疾病进展和改善患者预后方面令人鼓舞的结果。对包括基因疗法和干细胞疗法在内的新型治疗方法的持续研究，正在进一步扩展 ALS 治疗的前景。

此外，人们对肌萎缩侧索硬化症（ALS）的认识不断提高，以及相关专案研究计划的开展，推动了对有效治疗方法的需求。倡导团体和组织在提高公众意识和资金筹措发挥关键作用，从而促进了对ALS治疗的投入。同时，个人化医疗的兴起也影响ALS治疗市场，临床医师致力于根据患者的个别特征和遗传因素调整治疗方案。这种方法旨在提高治疗效果，并满足每位患者的独特需求。

此外，多学科诊疗模式的整合正在改变肌萎缩侧索硬化症（ALS）的治疗管理。神经科、物理治疗师、职业治疗师和营养师的协作对于提供全面护理至关重要，能够应对ALS患者面临的各种挑战。这种整体性方法不仅能提高患者的生活品质，还能在整个疾病历程中为患者及其家人提供支持。总之，ALS治疗市场有望迎来强劲成长，其特点是创新、公众意识的提高以及致力于改善这一充满挑战的治疗领域的患者照护。

目录

第一章 引言

第二章执行摘要

第三章 市场变数、趋势与框架

  • 市场谱系展望
  • 绘製渗透率和成长前景图
  • 价值链分析
  • 法律规范
    • 标准与合规性
    • 监管影响分析
  • 市场动态
    • 市场驱动因素
    • 市场限制
    • 市场机会
    • 市场问题
  • 波特五力分析
  • PESTLE分析

4. 全球肌萎缩侧索硬化症治疗药物市场

  • 市场分析、洞察与预测
  • Riluzole
  • Edaravone
  • 其他的

5. 全球肌萎缩侧索硬化症治疗市场（按类型划分）

  • 市场分析、洞察与预测
  • 散发性肌萎缩性侧索硬化症
  • 遗传性肌萎缩性侧索硬化症

6. 全球肌萎缩侧索硬化症治疗市场（依分销管道划分）

  • 市场分析、洞察与预测
  • 医院药房
  • 线上供应商
  • 药局和零售药房

7. 全球肌萎缩侧索硬化症治疗市场（按地区划分）

  • 区域分析
  • 北美市场分析、洞察与预测
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲市场分析、洞察与预测
    • 英国
    • 法国
    • 德国
    • 义大利
    • 俄罗斯
    • 其他欧洲国家
  • 亚太市场分析、洞察与预测
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 东南亚
    • 其他亚太国家
  • 拉丁美洲市场分析、洞察与预测
    • 巴西
    • 阿根廷
    • 秘鲁
    • 智利
    • 其他拉丁美洲国家
  • 中东和非洲市场分析、洞察与预测
    • 沙乌地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中东和非洲国家

第八章 竞争情势

  • 最新趋势
  • 公司分类
  • 供应链和销售管道合作伙伴（根据现有资讯）
  • 市场占有率和市场定位分析（基于现有资讯）
  • 供应商格局（基于现有资讯）
  • 策略规划

第九章：公司简介

  • 主要公司的市占率分析
  • 公司简介
    • Alkem Laboratories Ltd
    • Aquestive Therapeutics Inc
    • Italfarmaco SPA
    • Viatris Inc
    • Mitsubishi Chemical Group Corporation
    • Amylyx Pharmaceuticals Inc
    • Otsuka Pharmaceutical Co. Ltd
    • Glenmark Pharmaceuticals Limited
    • Covis Pharma GmbH
    • Sun Pharmaceutical Industries Ltd
简介目录
Product Code: VMR11216729

The Amyotrophic Lateral Sclerosis Treatment Market size is expected to reach USD 1260.33 Million in 2034 from USD 801.36 Million (2025) growing at a CAGR of 5.16% during 2026-2034.

The amyotrophic lateral sclerosis (ALS) treatment market is witnessing significant growth, driven by the increasing prevalence of this neurodegenerative disease and advancements in therapeutic options. ALS, characterized by the progressive degeneration of motor neurons, presents unique challenges in treatment due to its complex pathophysiology. However, recent developments in disease-modifying therapies, such as riluzole and edaravone, have shown promise in slowing disease progression and improving patient outcomes. Ongoing research into novel therapeutic approaches, including gene therapy and stem cell treatments, is further expanding the landscape of ALS management.

Moreover, the growing awareness of ALS and the establishment of dedicated research initiatives are propelling the demand for effective treatment options. Advocacy groups and organizations are playing a crucial role in raising awareness and funding research, leading to increased investment in ALS therapies. Additionally, the focus on personalized medicine is influencing the ALS treatment market, as clinicians seek to tailor interventions based on individual patient profiles and genetic factors. This approach aims to enhance treatment efficacy and address the unique needs of each patient.

Furthermore, the integration of multidisciplinary care models is transforming the management of ALS. Collaborative approaches involving neurologists, physical therapists, occupational therapists, and nutritionists are essential for providing comprehensive care that addresses the diverse challenges faced by ALS patients. This holistic approach not only improves quality of life but also supports patients and their families throughout the disease journey. In conclusion, the ALS treatment market is set for robust growth, characterized by innovation, increased awareness, and a commitment to improving patient care in this challenging therapeutic area.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drugs

  • Riluzole
  • Edaravone
  • Others

By Type

  • Sporadic ALS
  • Familial ALS

By Distribution Channel

  • Hospital Pharmacies
  • Online Providers
  • Drug Stores and Retail Pharmacies

COMPANIES PROFILED

  • Alkem Laboratories Ltd, Aquestive Therapeutics Inc, Italfarmaco SPA, Viatris Inc, Mitsubishi Chemical Group Corporation, Amylyx Pharmaceuticals Inc, Otsuka Pharmaceutical Co Ltd, Glenmark Pharmaceuticals Limited, Covis Pharma GmbH, Sun Pharmaceutical Industries Ltd

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET: BY DRUGS 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Drugs
  • 4.2. Riluzole Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Edaravone Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET: BY TYPE 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Type
  • 5.2. Sporadic ALS Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Familial ALS Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Distribution Channel
  • 6.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Online Providers Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Drug Stores and Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET: BY REGION 2022-2034(USD MN)

  • 7.1. Regional Outlook
  • 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.2.1 By Drugs
    • 7.2.2 By Type
    • 7.2.3 By Distribution Channel
    • 7.2.4 United States
    • 7.2.5 Canada
    • 7.2.6 Mexico
  • 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.3.1 By Drugs
    • 7.3.2 By Type
    • 7.3.3 By Distribution Channel
    • 7.3.4 United Kingdom
    • 7.3.5 France
    • 7.3.6 Germany
    • 7.3.7 Italy
    • 7.3.8 Russia
    • 7.3.9 Rest Of Europe
  • 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.4.1 By Drugs
    • 7.4.2 By Type
    • 7.4.3 By Distribution Channel
    • 7.4.4 India
    • 7.4.5 Japan
    • 7.4.6 South Korea
    • 7.4.7 Australia
    • 7.4.8 South East Asia
    • 7.4.9 Rest Of Asia Pacific
  • 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.5.1 By Drugs
    • 7.5.2 By Type
    • 7.5.3 By Distribution Channel
    • 7.5.4 Brazil
    • 7.5.5 Argentina
    • 7.5.6 Peru
    • 7.5.7 Chile
    • 7.5.8 South East Asia
    • 7.5.9 Rest of Latin America
  • 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.6.1 By Drugs
    • 7.6.2 By Type
    • 7.6.3 By Distribution Channel
    • 7.6.4 Saudi Arabia
    • 7.6.5 UAE
    • 7.6.6 Israel
    • 7.6.7 South Africa
    • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

  • 8.1. Recent Developments
  • 8.2. Company Categorization
  • 8.3. Supply Chain & Channel Partners (based on availability)
  • 8.4. Market Share & Positioning Analysis (based on availability)
  • 8.5. Vendor Landscape (based on availability)
  • 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT INDUSTRY

  • 9.1. Top Companies Market Share Analysis
  • 9.2. Company Profiles
    • 9.2.1 Alkem Laboratories Ltd
    • 9.2.2 Aquestive Therapeutics Inc
    • 9.2.3 Italfarmaco S.P.A
    • 9.2.4 Viatris Inc
    • 9.2.5 Mitsubishi Chemical Group Corporation
    • 9.2.6 Amylyx Pharmaceuticals Inc
    • 9.2.7 Otsuka Pharmaceutical Co. Ltd
    • 9.2.8 Glenmark Pharmaceuticals Limited
    • 9.2.9 Covis Pharma GmbH
    • 9.2.10 Sun Pharmaceutical Industries Ltd